Incyte Corporation

Company Profile

Incyte Corporation had its IPO on 1993-11-04 under the ticker symbol INCY.

The company operates in the Healthcare sector and Biotechnology industry. Incyte Corporation has a staff strength of 2,324 employees.

Stock update

Shares of Incyte Corporation opened at $61.5 at the start of the last trading session i.e. 2023-06-03.

The stocks traded within a range of $61.42 - $62.6, and closed at $62.54.

This is a +1.67% increase from the previous day's closing price.

A total volume of 1,760,400 shares were traded at the close of the day’s session.

In the last one week, shares of Incyte Corporation have slipped by -2.71%.

Incyte Corporation's Key Ratios

Incyte Corporation has a market cap of $13.95 billion, indicating a price to book ratio of 3.8229 and a price to sales ratio of 5.4924.

In the last 12-months Incyte Corporation’s revenue was $3.47 billion with a gross profit of $1.59 billion and an EBITDA of $575.70 million. The EBITDA ratio measures Incyte Corporation's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Incyte Corporation’s operating margin was 14.47% while its return on assets stood at 5.78% with a return of equity of 7.79%.

In Q1, Incyte Corporation’s quarterly earnings growth was a negative -42.7% while revenue growth was a positive 10.3%.

Incyte Corporation’s PE and PEG Ratio

Forward PE

14.9477

Trailing PE

43.131

PEG

0.4657

Its diluted EPS in the last 12-months stands at $1.45 per share while it has a forward price to earnings multiple of 14.9477 and a PEG multiple of 0.4657. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Incyte Corporation’s profitability.

Incyte Corporation stock is trading at a EV to sales ratio of 3.8964 and a EV to EBITDA ratio of 18.6307. Its price to sales ratio in the trailing 12-months stood at 5.4924.

Incyte Corporation stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$5.80 billion

Total Liabilities

$1.08 billion

Operating Cash Flow

$-28559000.00

Capital Expenditure

$11.91 million

Dividend Payout Ratio

0%

Incyte Corporation ended 2023 with $5.80 billion in total assets and $0 in total liabilities. Its intangible assets were valued at $5.80 billion while shareholder equity stood at $4.46 billion.

Incyte Corporation ended 2023 with $0 in deferred long-term liabilities, $1.08 billion in other current liabilities, 223000.00 in common stock, $-415511000.00 in retained earnings and $155.59 million in goodwill. Its cash balance stood at $2.82 billion and cash and short-term investments were $3.11 billion. The company’s total short-term debt was $3,149,000 while long-term debt stood at $0.

Incyte Corporation’s total current assets stands at $4.11 billion while long-term investments were $128.31 million and short-term investments were $291.66 million. Its net receivables were $623.79 million compared to accounts payable of $55.63 million and inventory worth $157.56 million.

In 2023, Incyte Corporation's operating cash flow was $-28559000.00 while its capital expenditure stood at $11.91 million.

Comparatively, Incyte Corporation paid $0 in dividends in 2023.

Other key metrics

Current Trading Price

$62.54

52-Week High

$86.29

52-Week Low

$60.71

Analyst Target Price

$82.24

Incyte Corporation stock is currently trading at $62.54 per share. It touched a 52-week high of $86.29 and a 52-week low of $86.29. Analysts tracking the stock have a 12-month average target price of $82.24.

Its 50-day moving average was $69.31 and 200-day moving average was $74.39 The short ratio stood at 3.55 indicating a short percent outstanding of 0%.

Around 153.2% of the company’s stock are held by insiders while 9651% are held by institutions.